The impact of age on response to injectable Semaglutide: ADA 2024 Abstract

Insights from the Association of British Clinical Diabetologists’ audit programme

THOMAS S.J. CRABTREE^1,2, KAREN ADAMSON³, ALEX BICKERTON⁴, ALISON EVANS⁵, SUZANNE M. PHILLIPS⁵, ALISON GALLAGHER⁶, DENNIS BARNES⁷, KETAN DHATARIYA8, BENJAMIN C. FIELD^9,10, ISKANDAR R. IDRIS^1,2, ROBERT E. RYDER¹¹, ON BEHALF OF ALL ABCD SEMAGLUTIDE AUDIT CONTRIBUTORS

1. University of Nottingham, UK; 
2. University Hospitals of Derby & Burton NHS Trust, UK; 
3. St John’s Hospital, UK; 
4. Yeovile District Hospital, UK; 
5. Gloucestershire Hospitals NHS Trust, UK; 
6. University Hospitals of Leicester NHS Trust, UK; 
7. Maidstone and Tunbridge Wells NHS Trust; 
8. The Norfolk and Norwich University Hospitals NHS Trust, UK; 
9. Surrey & Sussex Healthcare NHS Trust; 
10. University of Surrey, UK; 
11. Sandwell & West Birmingham Hospitals NHS Trust, UK